Abstract
Precision medicine seeks to treat disease with molecular specificity. Advances in genome sequence analysis, gene delivery, and genome surgery have allowed clinician-scientists to treat genetic conditions at the level of their pathology. As a result, progress in treating retinal disease using genetic tools has advanced tremendously over the past several decades. Breakthroughs in gene delivery vectors, both viral and nonviral, have allowed the delivery of genetic payloads in preclinical models of retinal disorders and have paved the way for numerous successful clinical trials. Moreover, the adaptation of CRISPR-Cas systems for genome engineering have enabled the correction of both recessive and dominant pathogenic alleles, expanding the disease-modifying power of gene therapies. Here, we highlight the translational progress of gene therapy and genome editing of several retinal disorders, including RPE65-, CEP290-, and GUY2D-associated Leber congenital amaurosis, as well as choroideremia, achromatopsia, Mer tyrosine kinase- (MERTK-) and RPGR X-linked retinitis pigmentosa, Usher syndrome, neovascular age-related macular degeneration, X-linked retinoschisis, Stargardt disease, and Leber hereditary optic neuropathy.
Introduction
The field of ophthalmology is currently witnessing a paradigm shift in the treatment of inherited retinal degenerations (IRDs). Historically considered untreatable, these conditions are now at the forefront of precision medicine. The transition from traditional gene supplementation—adding a functional gene copy—to "genome surgery," which utilizes tools like CRISPR-Cas9 to precisely edit or delete pathogenic mutations, marks a new era in genetic intervention. The eye’s unique anatomy and immune-privileged status have made it an ideal environment for testing these sophisticated molecular tools.
The Challenge of Retinal Degeneration
Inherited retinal degenerations comprise a diverse group of genetic disorders leading to progressive blindness. The primary challenge in treating these conditions lies in the delivery of genetic material to delicate, non-dividing neurons, such as photoreceptors and retinal pigment epithelium (RPE) cells, located deep within the eye.
Furthermore, the genetic mechanism of the disease dictates the required intervention. While recessive mutations (loss-of-function) can often be addressed by supplementing a healthy gene copy, dominant-negative mutations require the silencing or removal of the "bad" allele—a task that traditional gene therapy cannot perform.
Strategies for Genetic Intervention
Current technological approaches are broadly categorized into two main strategies: gene supplementation and genome surgery.
Gene Supplementation
This approach utilizes viral vectors to deliver exogenous DNA into target cells. Adeno-associated viruses (AAVs) are the current gold standard due to their low toxicity and high efficiency in transducing retinal cells. However, AAVs have a limited "cargo" capacity of approximately 4.5 kb. For larger genes, such as those involved in Stargardt disease (ABCA4) or Usher syndrome (MYO7A), lentiviruses or engineered dual-vector systems are employed.
Genome Surgery
Genome surgery leverages site-specific nucleases, primarily the CRISPR-Cas9 system, to modify the endogenous genome. This is particularly useful for diseases like LCA10 (CEP290), where the gene is too large for standard AAV delivery and the mutation creates a cryptic splice site. CRISPR can be used to excise the mutation, restoring normal protein production.
Clinical Progress and Key Insights
The success of gene therapy in the retina is exemplified by the FDA approval of Luxturna (AAV2-hRPE65v2) for RPE65-associated LCA. Clinical trials have demonstrated significant improvements in patient mobility and light sensitivity. Long-term data from canine models suggest that these treatments can be remarkably durable, with visual improvements persisting for over a decade after a single administration.
Another key insight is the feasibility of treating the second eye. Studies have shown that re-administration of the viral vector to the second eye, even years later, is safe and does not trigger a prohibitive immune response, despite the eye's initial exposure to the vector.
Limitations and Future Directions
Despite these advances, several hurdles remain. Most genome editing techniques, such as homology-directed repair (HDR), are most efficient in dividing cells. Since retinal neurons are post-mitotic, achieving precise "cut-and-paste" repair is technically challenging. Additionally, the timing of intervention is critical; gene therapy cannot restore vision if the target photoreceptors have already degenerated.
Future research is focusing on high-fidelity enzymes to minimize off-target effects and exploring optogenetics to restore light sensitivity to remaining non-sensory cells in late-stage disease. As the "bio-factory" concept matures, gene therapy may also replace chronic injections for common conditions like neovascular age-related macular degeneration (AMD) by enabling retinal cells to continuously produce therapeutic proteins.
Summary updated